What is Multiple Myeloma?
Multiple Myeloma is a type of blood cancer that affects plasma cells—a form of white blood cell found in the bone marrow. In this condition, abnormal plasma cells multiply uncontrollably, crowding out healthy blood cells and producing harmful proteins (M-proteins). This can lead to bone pain, anaemia, kidney damage, frequent infections, and weakened bones. It is most common in older adults (typically over 65), with a higher incidence among men and people of African descent.
This cancer typically progresses in stages, from a smouldering (asymptomatic) phase to more aggressive forms. Treatments depend on the disease stage and patient health, often involving chemotherapy, targeted therapies, immunotherapy, radiation, or stem cell transplants. India is increasingly chosen by international patients for its affordable yet advanced treatment options and high success rates.
Why Choose India for Multiple Myeloma Treatment?
India offers world-class treatment for multiple myeloma at leading Delhi-based and Tier 1 private hospitals such as Apollo Hospitals (Delhi), Fortis Memorial Research Institute (Gurugram), and Max Super Speciality Hospital (Saket), with access to:
- Top oncologists trained in global cancer centres
- Advanced therapies like proteasome inhibitors, CAR T-cell therapy, stem cell transplants, and monoclonal antibodies
- Multidisciplinary care including haematologists, nephrologists, and rehabilitation experts
- Fast-track diagnostics, and international patient services
Most importantly, cost is a major factor. Treatment in India is 70–90% more affordable than in Western countries. For example, stem cell transplants in India cost USD 14,000–38,000, compared to USD 200,000–400,000 in the U.S.
Cost & Duration Summary
Average Treatment Cost in India: USD 10,000 – 20,000
Hospital Stay (Stem Cell Transplant): 2 – 4 weeks
Post-Treatment Stay in India: 2 – 4 weeks